<DOC>
	<DOCNO>NCT00353418</DOCNO>
	<brief_summary>This 2-arm study compare efficacy safety treatment Pegasys ( 180 µg weekly ) plus Copegus ( 800 mg daily ) Pegasys ( 180 µg weekly ) plus Copegus ( 1000-1200 mg daily ) interferon-naive patient CHC genotype 1 co-infected HIV-1 . Treatment administer 48 week , follow 24 treatment-free week . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study PEGASYS ( Peginterferon Alfa-2a ( 40KD ) ) Plus COPEGUS ( Ribavirin ) Patients With Chronic Hepatitis C ( CHC ) Genotype 1 Human Immunodeficiency Virus-1 ( HIV-1 ) Co-infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , ≥18 year age CHC genotype 1 Stable HIV1 infection Previous treatment alpha interferon , ribavirin , viramidine , levovirin , amantadine investigational HCV protease polymerase inhibitor Medical condition associate liver disease CHC infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>